Apellis Pharmaceuticals, Inc.
APLS
$17.97
$0.080.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.94% | 132.98% | -10.61% | -3.21% | 45.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.94% | 132.98% | -10.61% | -3.21% | 45.19% |
| Cost of Revenue | -11.31% | -24.08% | -20.19% | 15.13% | 31.41% |
| Gross Profit | 0.67% | 389.75% | -0.80% | -31.74% | 66.69% |
| SG&A Expenses | 21.09% | 16.96% | 2.39% | -0.12% | -14.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.18% | -3.57% | -7.57% | 6.70% | 3.38% |
| Operating Income | -95.47% | 572.05% | -13.05% | -34.21% | 69.04% |
| Income Before Tax | -62.58% | 480.48% | -11.03% | -38.69% | 58.62% |
| Income Tax Expenses | 9.44% | 1.69% | 308.77% | 100.59% | -79.90% |
| Earnings from Continuing Operations | -62.16% | 475.52% | -11.93% | -38.84% | 58.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.16% | 475.52% | -11.93% | -38.84% | 58.96% |
| EBIT | -95.47% | 572.05% | -13.05% | -34.21% | 69.04% |
| EBITDA | -97.59% | 577.38% | -13.26% | -34.45% | 69.40% |
| EPS Basic | -59.44% | 469.01% | -10.07% | -36.08% | 60.05% |
| Normalized Basic EPS | -59.83% | 473.92% | -15.15% | -35.93% | 59.72% |
| EPS Diluted | -67.39% | 461.16% | -10.07% | -36.08% | 60.05% |
| Normalized Diluted EPS | -59.83% | 463.43% | -15.15% | -35.93% | 59.72% |
| Average Basic Shares Outstanding | 1.72% | 1.76% | 1.71% | 2.03% | 2.71% |
| Average Diluted Shares Outstanding | 1.72% | 4.70% | 1.71% | 2.03% | 2.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |